India, June 25 -- President Donald Trump was at the center of two high-profile meetings on Tuesday afternoon. He first attended a meeting with GOP Senators, followed by an Oval Office meeting with NATO General Secretary, Mark Rutte, in what turned out to be a very busy afternoon for the 79-year-old.

Amid all the business, concerns around Trump's health persisted, as, earlier on Tuesday, a report claimed Trump may be taking an experimental weight loss drug called retatrutide, made by the drug-maker Eli Lilly, through the Federal Drug Administration's "compassionate use" program. The program allows terminally ill patients to experimentally use drugs not yet approved for public use by the FDA.

The claim first surfaced on STAT News. The out...